The European Association of Urology (EAU) produces an annual guidelines document based on the most recent evidence for the diagnosis, treatment, and follow-up of testicular cancer (TC). To summarize the 2026 version of the EAU Guidelines on TC and highlight the main changes compared to the previous version.
A multidisciplinary team of clinicians with specific expertise in the disease (urologists, medical oncologists, radiation oncologists, and pathologists) reviewed the results of a comprehensive appraisal of the published literature on the topic since the last Guidelines update paper in 2023.
Recommendations based on the highest available level of evidence are presented across TC stages, histologies and prognostic categories regarding diagnosis, primary management, detection and treatment of relapse and survivorship care. Areas of lack of strong recommendation consensus are highlighted.
The 2026 version of the EAU Guidelines on TC collates the highest available scientific evidence to standardize the management of patients with TC.
European urology. 2026 Apr 27 [Epub ahead of print]
Anna Patrikidou, Walter Cazzaniga, Christoph Oing, Daniel Berney, Joao Lobo, Joost Boormans, Christian Fankhauser, Stefanie Fischer, Ricardo Leao, Carmen Gravina, Domenico Di Nardo, Robert Cornes, Florian Janisch, Carla Bezuidenhout, Hege Sagstuen Haugnes, Alexandros Papachristofilou, Torgrim Tandstad, Axel Heidenreich
Genitourinary Oncology Group, Department of Medical Oncology and Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: ., Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK., Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK and The Northern Centre for Cancer Care, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Centre of Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Charterhouse Square, Queen Mary University of London, London, UK., Department of Pathology and Cancer Biology and Epigenetics Group-Research Centre, Portuguese Oncology Intituto of Porto (IPO Porto), Porto, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciencces Abel Salazar, Univeristy of Porto (ICBAS-UP), Porto, Portugal., Department of Urology, Erasmus University Medical Centre - Cancer Institute, Rotterdam, the Netherlands., Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland., Department of Medical Oncology and Hematology; Health Ostschweiz/Cantonal Hospital St. Gallen, St. Gallen, Switzerland., CUF Hospitals, iCBR, Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Department of Urology, Sant'Andrea Hospital-Sapienza University, Rome, Italy., Patient Representative, European Association of Urology Guidelines Office, Arnhem, the Netherlands., Orchid Male Cancer, London, UK., Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., European Association of Urology Guidelines Office, Arnhem, the Netherlands., Department of Oncology, University Hospital of North Norway, Tromsoe, Norway; Department of Clinical Medicine, UIT-The Arctic Uniersity, Tromsoe, Norway., Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland., Department of Oncology, The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway., Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Germany.